Market Research Report
Continuous Renal Replacement Therapy (CRRT) Market by Product (Systems, Disposables (Hemofilters & Bloodlines), & Dialysate), Modality (SCUF, CVVH, CVVHD, CVVHDF), Adoption & Procedures, Region (Europe, North America, Asia-Pacific) - Forecast to 2022
|Published by||MarketsandMarkets||Product code||344289|
|Published||Content info||189 Pages
Delivery time: 1-2 business days
|Continuous Renal Replacement Therapy (CRRT) Market by Product (Systems, Disposables (Hemofilters & Bloodlines), & Dialysate), Modality (SCUF, CVVH, CVVHD, CVVHDF), Adoption & Procedures, Region (Europe, North America, Asia-Pacific) - Forecast to 2022|
|Published: July 20, 2017||Content info: 189 Pages||
The global CRRT market is projected to reach USD 1.53 billion by 2022 from USD 1.09 billion in 2017, at a CAGR of 7.0%. Increasing global incidence of acute kidney injury, growing number of ICU patients, increasing incidence of sepsis, and tehcnologcal advancements are some of the factors driving the growth of the CRRT market. However, high procedural cost of CRRT and stringent regulatory guidelines for CRRT in North America are expected to hinder market growth.
On the basis of product, CRRT disposables segment is further sub-segmented to the bloodline sets, hemofilters, and other disposables (such as vascular access catheters and CRRT accessories, including drainage bags, ancillaries, stop cocks, syringes, and priming solutions). The hemofilters segment is estimated to account for the largest share of the disposables market due to the development of novel hemofilters and their increasing use in CRRT procedures.
Based on modality, the CRRT market is segmented into slow continuous ultrafiltration (SCUF), continuous venovenous hemofiltration (CVVH), continuous venovenous hemodialysis (CVVHD), and continuous venovenous hemodiafiltration (CVVHDF). The The CVVH modality is estimated to account for the largest share of the global CRRT market owing to the wide adoption of this modality among healthcare providers.
Geographically, the CRRT market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. Asia-Pacific is expected to register the highest growth rate during the forecast period, owing to the large acute kidney injury patient population, high utilization of CRRT in Australia and Japan, and improving healthcare infrastructure across Asian countries.
The major players in the market are Baxter International Inc. (U.S.), Fresenius Medical Care AG & Co. KGaA (Germany), Nikkiso Co., Ltd. (Japan), B. Braun Melsungen AG (Germany), Bellco S.r.l. (Italy), NxStage Medical, Inc. (U.S.), Asahi Kasei Corporation (Japan), Infomed SA (Switzerland), and Medica S.p.A. (Italy), and Toray Medical Co., Ltd. (Japan).
This report studies the CRRT market based on product and modality. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and prospects in the total market. The report forecasts the revenue of the market segments with respect to four main regions.
From an insights perspective, this research report has focused on various levels of analysis-industry trends, market share analysis of top ten players, and company profiles, which together comprise and discuss basic views on the competitive landscape, emerging and high-growth segments of the CRRT market, and high-growth regions and countries and their respective drivers, restraints, challenges, and opportunities.
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn help firms garner greater market shares. Firms purchasing the report could use any one or a combination of the recommended strategies for strengthening their market shares.
Top 25 companies analyzed for this studies are - Baxter International Inc. (U.S.), Fresenius Medical Care AG & Co. KGaA (Germany), NxStage Medical, Inc. (U.S.), NIKKISO CO., LTD. (Japan), B. Braun Melsungen AG (Germany), Asahi Kasei Corporation (Japan), Bellco S.r.l. (Italy), Toray Medical Co., Ltd. (Japan), Infomed SA (Switzerland), Medica S.p.A. (Italy), Medical Components, Inc. (U.S.), Medites Pharma spol. s.r.o. (Czech Republic), Medtronic plc (Ireland), SWS Hemodialysis Care Co., Ltd. (China), Ningbo Tianyi Medical Devices Co., Ltd (China), CytoSorbents Corporation (U.S.), BIOMEDICA spol. s r.o. (Czech Republic), Anjue Medical Equipment Co., Ltd. (China), Jiangxi Sanxin Medtec Co., Ltd. (China), Proxima Medicare (India), Nipro Corporation (Japan), CytoPherx, Inc. (U.S.), Dialysis Solutions Inc. (U.S.), Kimal Electronics Ltd (U.K.), BL Lifesciences (India)
*Details on MarketsandMarkets view, Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, and Recent Developments might not be captured in case of unlisted companies.